Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, IBR Tower, Level 2, Birmingham, B15 2TT, UK.
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, B15 2TH, UK.
Pituitary. 2018 Apr;21(2):203-207. doi: 10.1007/s11102-018-0863-9.
Non-functioning pituitary adenomas (NFA) are benign pituitary neoplasms not associated with clinical evidence of hormonal hypersecretion. A substantial number of patients with NFA have morbidities related to the tumor and possible recurrence(s), as well as to the treatments offered. Studies assessing the long-term mortality of patients with NFA are limited. Based on the published literature of the last two decades, overall, the standardized mortality ratios in this group suggest mortality higher than that of the general population with deaths attributed mainly to circulatory, respiratory and infectious causes. Women seem to have higher mortality ratios, and assessment of time trends suggests improvement over the years. There is no consensus on predictive factors of mortality but those most consistently identified are older age at diagnosis and high doses of glucocorticoid substitution therapy. Well designed and of adequate power studies are needed to establish the significance of factors compromising the survival of patients with NFA and to facilitate improvements in long-term prognosis.
无功能性垂体腺瘤(NFA)是一种良性垂体肿瘤,与激素过度分泌的临床证据无关。相当数量的 NFA 患者存在与肿瘤相关的以及可能复发的疾病,还有与之相关的治疗方法。评估 NFA 患者长期死亡率的研究是有限的。基于过去二十年的文献,总的来说,该组患者的标准化死亡率比高于普通人群,死亡主要归因于循环、呼吸和感染原因。女性似乎死亡率更高,并且随着时间的推移,趋势评估表明有所改善。目前尚无死亡率预测因素的共识,但最一致的发现是诊断时年龄较大和糖皮质激素替代治疗剂量较高。需要进行设计良好且有足够效力的研究,以确定影响 NFA 患者生存的因素的重要性,并改善长期预后。